Immunogenicity of SARS inactivated vaccine in BALB/c mice.
Identifieur interne : 005303 ( Main/Exploration ); précédent : 005302; suivant : 005304Immunogenicity of SARS inactivated vaccine in BALB/c mice.
Auteurs : Sheng Xiong [République populaire de Chine] ; Yi-Fei Wang ; Mei-Ying Zhang ; Xin-Jian Liu ; Chuan-Hai Zhang ; Shi-Sheng Liu ; Chui-Wen Qian ; Jiu-Xiang Li ; Jia-Hai Lu ; Zhuo-Yue Wan ; Huan-Yin Zheng ; Xin-Ge Yan ; Min-Jie Meng ; Jiang-Lin FanSource :
- Immunology letters [ 0165-2478 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Antigènes viraux (immunologie), Cinétique, Immunoglobuline G (immunologie), Immunoglobuline G (sang), Souris, Souris de lignée BALB C, Spécificité des anticorps, Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Sérums immuns (immunologie), Tests de neutralisation, Vaccins antiviraux (immunologie), Vaccins inactivés (immunologie), Virus du SRAS (immunologie).
- MESH :
- immunologie : Anticorps antiviraux, Antigènes viraux, Immunoglobuline G, Syndrome respiratoire aigu sévère, Sérums immuns, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- sang : Anticorps antiviraux, Immunoglobuline G.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Cinétique, Souris, Souris de lignée BALB C, Spécificité des anticorps, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Specificity, Antigens, Viral (immunology), Immune Sera (immunology), Immunoglobulin G (blood), Immunoglobulin G (immunology), Kinetics, Mice, Mice, Inbred BALB C, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Vaccines, Inactivated (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , immunology : Antibodies, Viral, Antigens, Viral, Immune Sera, Immunoglobulin G, Vaccines, Inactivated, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Antibody Specificity, Kinetics, Mice, Mice, Inbred BALB C, Neutralization Tests.
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.
DOI: 10.1016/j.imlet.2004.06.014
PubMed: 15388253
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002B45
- to stream PubMed, to step Curation: 002B45
- to stream PubMed, to step Checkpoint: 002C54
- to stream Ncbi, to step Merge: 000A83
- to stream Ncbi, to step Curation: 000A83
- to stream Ncbi, to step Checkpoint: 000A83
- to stream Main, to step Merge: 005712
- to stream Main, to step Curation: 005303
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of SARS inactivated vaccine in BALB/c mice.</title><author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name><affiliation wicri:level="1"><nlm:affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name></author><author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name></author><author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name></author><author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name></author><author><name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name></author><author><name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name></author><author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name></author><author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name></author><author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name></author><author><name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name></author><author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name></author><author><name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name></author><author><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15388253</idno><idno type="pmid">15388253</idno><idno type="doi">10.1016/j.imlet.2004.06.014</idno><idno type="wicri:Area/PubMed/Corpus">002B45</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B45</idno><idno type="wicri:Area/PubMed/Curation">002B45</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B45</idno><idno type="wicri:Area/PubMed/Checkpoint">002C54</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C54</idno><idno type="wicri:Area/Ncbi/Merge">000A83</idno><idno type="wicri:Area/Ncbi/Curation">000A83</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A83</idno><idno type="wicri:doubleKey">0165-2478:2004:Xiong S:immunogenicity:of:sars</idno><idno type="wicri:Area/Main/Merge">005712</idno><idno type="wicri:Area/Main/Curation">005303</idno><idno type="wicri:Area/Main/Exploration">005303</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity of SARS inactivated vaccine in BALB/c mice.</title><author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name><affiliation wicri:level="1"><nlm:affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name></author><author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name></author><author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name></author><author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name></author><author><name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name></author><author><name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name></author><author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name></author><author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name></author><author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name></author><author><name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name></author><author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name></author><author><name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name></author><author><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name></author></analytic><series><title level="j">Immunology letters</title><idno type="ISSN">0165-2478</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Antibody Specificity</term><term>Antigens, Viral (immunology)</term><term>Immune Sera (immunology)</term><term>Immunoglobulin G (blood)</term><term>Immunoglobulin G (immunology)</term><term>Kinetics</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vaccines, Inactivated (immunology)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (sang)</term><term>Antigènes viraux (immunologie)</term><term>Cinétique</term><term>Immunoglobuline G (immunologie)</term><term>Immunoglobuline G (sang)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Sérums immuns (immunologie)</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Antigens, Viral</term><term>Immune Sera</term><term>Immunoglobulin G</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Antigènes viraux</term><term>Immunoglobuline G</term><term>Syndrome respiratoire aigu sévère</term><term>Sérums immuns</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Specificity</term><term>Kinetics</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cinétique</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Guangdong</li></region><settlement><li>Jiangmen</li></settlement></list><tree><noCountry><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name><name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name><name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name><name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name><name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name></noCountry><country name="République populaire de Chine"><region name="Guangdong"><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005303 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005303 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15388253
|texte= Immunogenicity of SARS inactivated vaccine in BALB/c mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15388253" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |